Proove Biosciences Again Successfully Presents Genetic Research at the American Pain Society’s 33rd Annual Scientific Meeting

Proove Biosciences was again the only company presenting evidence-based research on how genetic testing can improve efficiency and effectiveness of cancer pain management.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
"Proove continues to lead the industry in research and commercially-available pain medicine genetic testing, evident by our highly regarded PAIN Study, and now the SPORT Study." - Brian Meshkin, CEO, Proove Biosciences

Irvine, CA (PRWEB) May 05, 2014

Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented clinical data on how their genetic tests have been helping physicians improve patient pain treatment outcomes at The American Pain Society’s 33rd Annual Scientific Meeting this week. Proove is consistently the only company exhibiting scientific data and research on how genetic analysis can help determine how a patient will react to narcotic prescriptions.

Proove specifically presented their new Stratifying Patient Opioid Risk Tool (ORT) Scores Using Genetic Predisposition of Dopaminergic Imbalances (S.P.O.R.T. Study). The SPORT Study aims to evaluate the relationship between the ORT and a panel of single nucleotide polymorphisms in the mesolimbic dopamine system to stratify patients between high, moderate, and low risk to misuse opioid pain medications.

The study involved 290 subjects across 15 clinical research sites, where patients completed an ORT, and were genotyped with TaqMan single nucleotide polymorphisms assays utilizing the proprietary Proove Narcotic Risk Genetics Profile Test.

The study found the average Narcotic Risk Index scores (NRI) for high risk ORT scores was 20 compared to 19 for low risk ORT scores. However, when looking at individual SNPs, a genotype of 4 homozygous mutations was found to stratify between high, moderate, and low risk for opioid abuse, when correlated to the ORT.

Homozygous mutations in the dopamine d2 receptor A1 allele (23.91% v. 11.48%), dopamine d1 receptor DRD1 -d/G (12.77% v. 10.93%), dopamine beta hydroxylase DBH -1021 C/T (19.15% v 10.38%, and GABA alpha 6 gene -1519T>C (25.53% v. 13.66% were more prevalent among high ORT scores versus moderate and low ORT scores.

“Proove continues to lead the industry in research and commercially-available pain medicine genetic testing, evident by our highly regarded PAIN Study, and now the SPORT Study,” stated Proove CEO Brian Meshkin. “We are the only company able to supply scientific data and research on how genetics influence the perception and management of pain. It is always exciting to share how our research is bringing efficiency to the healthcare system at premier events such as the American Pain Society’s 33rd Annual Scientific Meeting, and continue building on our positive momentum in the industry.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).


Contact